Research Updates

Back to project

Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome): update of November 2, 2026

What's new and why it matters

  1. A study found that polidocanol sclerotherapy can greatly reduce nosebleeds in people with HHT, and many reported feeling hopeful about this treatment. Based on: 1
  2. A new study is being planned to explore if daily use of Pazopanib for 24 weeks can help lessen nosebleeds and anemia in HHT patients. Based on: 2

Materials in this update

  1. Operating-room polidocanol sclerotherapy for HHT-related epistaxis.
    PubMed

    Oct 31, 2026

    A study showed that using polidocanol sclerotherapy significantly reduced nosebleeds in patients with HHT, with many feeling positive about the treatment.

  2. Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
    Clinical trials

    Registered study, no results yet

    Oct 27, 2026

    This planned study aims to see if taking Pazopanib daily for 24 weeks can lessen the severity of nosebleeds in patients with HHT.

All updates for Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome)
Email language